Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See
full details
.
I Agree
×
Join today and have your say! It’s FREE!
Join Now
Sign In
Become a member today, It's free!
We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.
Join Today
or
Sign in with existing account
Privacy Policy
|
Disclaimer
Sign In
Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Remember me
Forgot Password?
Sign In
or
Sign Up
Privacy Policy
|
Disclaimer
Please Try Again
{{ error }}
Send my password
Submit
Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.
Become a member today, It's free!
We will not release or resell your information to third parties without your permission.
Linking with Facebook:
Stockhouse membership requires an email address which must be shared by Facebook.
By default, joining or signing in using your Facebook account will work and the email address will be shared by Facebook automatically.
If you change your Facebook permissions to restrict Stockhouse from receiving your email while joining or signing in to Stockhouse then it will fail.
Please do not modify the permission settings during sign-in.
Sign in with Facebook
Return to Signup Options
Home
Community
Bullboards
Blogs
Groups
Messages
Markets
Stocks
TSX
TSXV
CSE
NASDAQ
NYSE
NYSE American
Cryptocurrency
Currencies
Market Movers
Bonds
News
Featured News
Trending News
Canadian Press Releases
US Press Releases
Video
Editorial
Thematic Insights
Independent Reports
Interviews
Buzz on the Bullboards
Portfolio
Watchlist
Portfolio
Showcase Companies
DealRoom
Quote
|
Bullboard
|
News
|
Opinion
|
Profile
|
Peers
|
Filings
|
Financials
|
Options
|
Price History
|
Ratios
|
Ownership
|
Insiders
|
Valuation
Bullboard - Stock Discussion Forum
NurExone Biologic Inc.
NRXBF
Primary Symbol:
V.NRX
Healthcare
Biotechnology
NurExone Biologic Inc. is a biopharmaceutical company. The Company is developing and commercializing an exosome therapy ExoTherapy production platform and products for a global market. It is involved in the development of ExoPTEN, the first ExoTherapy-based product for acute Spinal Cord Injuries (SCI). The Company is developing treatment for the reversal or reduction of paralysis following...
spinal cord injury (SCI) using Exosomes (membrane-bound extracellular vesicles). This technology, subject to conducting clinical trials and receiving Food and Drug Administration (the FDA) approval, can be used in various conditions such as SCI, Brain Trauma Injury (BTI), and potentially other brain and neurological indications.
see more
Get updates on NurExone Biologic Inc. delivered in your email.
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
I consent to receiving electronic messages from NurExone Biologic Inc. and Stockhouse.
Join the community and start posting on the bullboards today. It's free.
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
Create a portfolio watchlist today. It's free.
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
Company Website
Add To Watchlist
Bullboard (TSXV:NRX)
New Post
View:
Posts & Comments
Threaded Posts
Prev
1
2
3
4
Next
•••
Jonathon Brown
X
View Profile
View Bullboard History
Post by
Jonathon Brown
on May 30, 2024 5:01am
Buzz on the Bullboards: Volatility persists in the face of economic indicators
Canada’s main stock index struggled and the NASDAQ hit a high, demonstrating a continued appetite for tech stocks amidst market volatility.
read article.
(0)
•••
PressRelease
X
View Profile
View Bullboard History
Post by
PressRelease
on May 29, 2024 8:35am
New Press Release - NurExone Reports First Quarter 2024 Financial Results and Provides Corporate Update, moving forward with FDA guidelines for the Human Trials
TORONTO and HAIFA, Israel, May 29, 2024 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX) (OTCQB: NRXBF) (Germany: J90) (the “Company” or “NurExone”), a pioneering biopharmaceutical company developing regenerative medicine therapies, is pleased to announce its financial and operational...
read article.
A Strategic Focus on Technology-Driven AI-Powered Healthcare Solutions
posted Jun 03, 2024 9:00am by
Safe Supply Streaming Co Ltd.
-
|
The AI-powered healthcare market is set to revolutionize the industry, with the market size expected to grow from $6.9 billion in 2021 to $67.4 billion by 2027, at a CAGR of 44.9%. Technology driven solutions around mental health, counselling, addiction, and harm reduction testing provide the most attractive and strategic opportunities ...read more
(14)
•••
Brice978
X
View Profile
View Bullboard History
Post by
Brice978
on May 24, 2024 4:26pm
NurExone's Expands Commercialization Efforts with All-star H
https://10xalerts.com/nurexones-expands-commercialization-efforts-with-all-star-hire-tsxv-nrx/
(0)
•••
PressRelease
X
View Profile
View Bullboard History
Post by
PressRelease
on May 17, 2024 4:04pm
New Press Release - NurExone Welcomes Biopharma Exec Dr. Ram Petter to Drive Strategic Collaborations
TORONTO and HAIFA, Israel, May 17, 2024 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX), (OTCQB: NRXBF), (Germany: J90) (the “Company” or “NurExone”), a pioneering biopharmaceutical company, proudly welcomes Dr. Ram Petter, Ph.D., MBA, as a consultant, to assist in driving the Company’s...
read article.
(58)
•••
88guy88
X
View Profile
View Bullboard History
Post by
88guy88
on May 14, 2024 11:33am
2.5 years to break even for this company
thats a long wait for a maybe....this one is for patient speculators only.....no quick trade flip here....go try those meme stocks for a rush 34,500 shares for sale at 53 cents and only 3000 bid at
...more
(58)
•••
88guy88
X
View Profile
View Bullboard History
Post by
88guy88
on May 13, 2024 12:09pm
Wait for 41 cents
looks like it wants to head back to the 200 day moving average which is 41 cents....no news or results for a long time while they do research now....thin trader.....good luck!
(58)
•••
88guy88
X
View Profile
View Bullboard History
Post by
88guy88
on May 03, 2024 10:03am
100,000 shares are for sale at 63 cents
only a few thousand shares on the offers in the 50s.....here we go!
(0)
•••
PressRelease
X
View Profile
View Bullboard History
Post by
PressRelease
on Apr 25, 2024 8:35am
New Press Release - NurExone Biologic Inc. Announces Strategic Expansion to US Financial Markets with Approval of OTCQB Listing Application and DTC Eligibility
TORONTO and HAIFA, Israel, April 25, 2024 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX) (Germany: J90) (the “Company” or “NurExone”), a pioneering biopharmaceutical company is pleased to announce that its common shares are now quoted for trading on the OTCQB® Venture Market (the "OTCQB")...
read article.
(0)
•••
PressRelease
X
View Profile
View Bullboard History
Post by
PressRelease
on Apr 19, 2024 4:04pm
New Press Release - NurExone Presenting on Revolutionary Spinal Cord Injury Therapy at European Conference on Exosomes and Regenerative Medicine
TORONTO and HAIFA, Israel, April 19, 2024 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX) (Germany: J90) (the “Company” or “NurExone”), a pioneering biopharmaceutical company, is pleased to announce that Dr. Lior Shaltiel, CEO and Director at NurExone, was invited to present on...
read article.
(7)
•••
Mathew177
X
View Profile
View Bullboard History
Post by
Mathew177
on Apr 19, 2024 10:46am
NurExone Unlocks Several Milestones Since March 2024
NurExone Unlocks Several Milestones Since March 2024 (TSXV: NRX, FSE: J90, NRX.V) https://10xalerts.com/nurexone-unlocks-several-milestones-since-march-2024-tsxv
...more
(58)
•••
88guy88
X
View Profile
View Bullboard History
Post by
88guy88
on Apr 16, 2024 12:44pm
This one is a thin trader and no buyer interest
did not hold the 60 cent level ....so likely down she goes.....no news to move it up and establishing a home base in Israel is probably not the best location....talk about adding extra risk to the
...more
(58)
•••
88guy88
X
View Profile
View Bullboard History
Post by
88guy88
on Apr 12, 2024 2:07pm
Price is below the 20 and 50 day average of 70 cents
the 200 day average support is at 38 cents......appears to be bouncing of the 60 cent base but if it falls below that 60....look out below......could go back to test 38 cents....Cheers!
(0)
•••
PressRelease
X
View Profile
View Bullboard History
Post by
PressRelease
on Apr 02, 2024 8:31am
New Press Release - NurExone Reports Fourth Quarter and Year Ended December 31, 2023 Financial Results and Provides Company Update
TORONTO and HAIFA, Israel, April 02, 2024 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX) (Germany: J90) (the “Company” or “NurExone”), a pioneering biopharmaceutical company, developing regenerative medicine therapies, today provided a business update and reported financial results for...
read article.
(0)
•••
PressRelease
X
View Profile
View Bullboard History
Post by
PressRelease
on Mar 27, 2024 5:05pm
New Press Release - Gross Proceeds Close of $4M CAD Generated for NurExone From Warrants Exercise
TORONTO and HAIFA, Israel, March 27, 2024 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX) (Germany: J90) (the “Company” or “NurExone”), is pleased to announce that, the Company completed a combined exercise and expiration of 12,682,340 common share purchase warrants issued pursuant to a...
read article.
(0)
•••
PressRelease
X
View Profile
View Bullboard History
Post by
PressRelease
on Mar 22, 2024 5:04pm
New Press Release - In Preparation for Expected Human Clinical Trials, NurExone Signs Agreement for Large Scale Preclinical Testing for Its Spinal Cord Injury Therapy, ExoPTEN
Leading Contract Research Organization to carry out pharmacological studies, part of planned FDA Investigational New Drug (IND) application TORONTO and HAIFA, Israel, March 22, 2024 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX) (Germany: J90) (the “Company” or “NurExone”), a pioneering...
read article.
(7)
•••
Mathew177
X
View Profile
View Bullboard History
Post by
Mathew177
on Mar 20, 2024 12:38pm
The Rise of NurExone Biologic Inc. in Biopharma (TSXV: NRX)
The Rise of NurExone Biologic Inc. in Biopharma (TSXV: NRX, FSE: J90, NRX.V) https://10xalerts.com/the-rise-of-nurexone-biologic-inc-in-biopharma-tsxv-nrx-fse-j90-nrx-v/
Prev
1
2
3
4
Next
Thank You
Your Report has been submitted.
Report Abusive Content
×
Close
Sign up to get access
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
The Market Update
{{currentVideo.title}}
{{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >
A daily snapshot of everything
from market open to close.
{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}
{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >
Featured News Links
This Small-Cap Gold Stock Jumped Almost 50% on Friday
A Junior Copper-Gold Stock Trading at a Bargain of Monumental Proportions
Leading Intermediate Drilling Co. Poised to Capitalize on Market Conditions